RAP-219 for Adults With Focal Seizures
Tests RAP-219 against a placebo in adults with focal seizures.
Plain-language title generated from the registry record
Registry title: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Key facts
- Where
- Bentonville, Chicago, Colorado Springs, Honolulu, Houston, Huntsville, Maitland, Miami, Nashville, New York, Omaha, and Raleigh, United StatesSee the 13 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07594119, who can take part
Where in United States
- Pillar Clinical ResearchBentonville, United StatesTaking people
- Re:Cognition Health - ChicagoChicago, United StatesTaking people
- Colorado Springs Neurological AssociatesColorado Springs, United StatesTaking people
- Hawaii Pacific NeuroscienceHonolulu, United StatesTaking people
- Baylor College of MedicineHouston, United StatesTaking people
- University of Texas Health Science Center in HoustonHouston, United StatesTaking people
- Clinic for NeurologyHuntsville, United StatesTaking people
- K2 Medical ResearchMaitland, United StatesTaking people
- Serenity Research Center, LLCMiami, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- Lenox Hill HospitalNew York, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- Velocity Clinical ResearchRaleigh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rapport Therapeutics Inc.
- Trial code
- NCT07594119
- Record updated
- 6 November 2026
- Original description
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.Read full original descriptionShow less
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Inclusion: Age 18 - 75; BMI 18-45 kg/m2; Diagnosis of focal epilepsy for ≥24 months prior to Visit 1; Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis; Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs; Ability to keep accurate daily focal seizure records using an e-diary.
Exclusion: Known hypersensitivity or prior exposure to RAP-219; Anticipated need for surgery during the study period; Medical history of any of the following:; generalized epilepsy; focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type; psychogenic nonepileptic seizure (PNES); status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56); epilepsy surgery within 12 months prior to Visit 1 (Day -56); Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product; Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur.